Merck & Co., Inc., disclosed in its August 8, 2011, Form 10-Q filing with the U.S. Securities and Exchange Commission for the quarter ended June 30, 2011, that expert discovery in the NuvaRing litigation is expected to be completed by…
In July 2011, the United States District Court for the District of Massachusetts dismissed the majority of Plaintiff’s claims in the lawsuit captioned United States of America ex rel Tricia Nowak and Enda Dodd v. Medtronic, Inc., according to the…
Merck & Co., Inc., is awaiting a court decision on its motion to dismiss a derivation action captioned Rose v. Hassan, according to the Company’s August 8, 2011, Form 10-Q filing with the U.S. Securities and Exchange Commission for the…
Merck & Co., Inc., continues to defend lawsuits relating to average wholesale prices pending in various states, according to the Company’s August 8, 2011, Form 10-Q filing with the U.S. Securities and Exchange Commission for the quarter ended June 30,…
The U.S. District Court for the Southern District of New York granted in April 2011 final approval of the settlement agreement with regards to In re Pfizer Inc. Shareholder Derivative Litigation, the company disclosed in its latest quarterly report on…
The U.S. Internal Revenue Service (IRS) is currently auditing the 2006, 2007 and 2008 tax years for Pfizer Inc, the company disclosed in its latest quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission.
The 2009 through…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that the Texas Supreme Court has granted Merck s petition for review and scheduled oral argument for January 20,…
During the first nine months of 2009, Merck & Co. Inc. spent approximately US$190 million in the aggregate in legal defense costs worldwide, including US$65 million in the third quarter of 2009.
The legal expenses were related to (i) the Vioxx…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it is cooperating with U.S. Attorney s Office for the District of Massachusetts.
In March 2009, Merck received a…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that in the MDL proceeding of the Vioxx dispute, the trial of the Louisiana Attorney General case is scheduled…